The Cost Support Program for TRUXIMA® (rituximab-abbs) injection (the "Program") helps commercially insured patients in the United States (including the United States territories) who are prescribed TRUXIMA for covered indications pay for their eligible out-of-pocket costs. Terms may vary by indication.
Full Answer
What is the Rituxan immunology co-pay program?
Rituxan Immunology Access Solutions can refer eligible patients to the Rituxan Immunology Co-pay Program for help with the out-of-pocket costs associated with Rituxan.* For eligible patients with commercial or public health insurance, Rituxan Immunology Access Solutions offers referrals to independent co-pay assistance foundations.†
Where can I get Rituxan for free?
The Genentech Patient Foundation provides free Rituxan to people who don't have insurance coverage or who have financial concerns and meet eligibility criteria.*
What should I do if I have a reaction to Rituxan?
Your healthcare provider should give you medicines before your infusion of Rituxan to decrease your chance of having a severe infusion-related reaction. Tell your healthcare provider or get medical help right away if you get any of these symptoms during or after an infusion of Rituxan: Swelling of your lips, tongue, throat, or face
Is it safe to take Rituxan while breastfeeding?
Rituxan may pass into your breast milk. Do not breastfeed during treatment and for 6 months after your last dose of Rituxan are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your doctor if you take or have taken: What are the possible side effects of Rituxan?
Is patient assistance program legitimate?
Patient assistance programs (PAPs) are usually sponsored by pharmaceutical manufacturers and are promoted as a safety net for Americans who have no health insurance or are underinsured.
How do you feel after Rituxan?
After a Rituxan (rituximab) infusion you may experience certain side effects or adverse reactions that make you feel unwell. Rituxan affects different people in different ways, but the more common side effects include: Fever (high temperature), muscle aches, headaches and chills, which are signs of infection.
What is Allergan patient assistance program?
The Allergan Patient Assistance Program (PAP) provides Allergan medicines at no cost to eligible patients. If the patient qualifies, up to a twelve-month eligibility for the requested medication(s) or device(s) is approved for shipment to the patient's licensed prescriber for dispensing.
Can you drink after rituximab infusion?
Alcohol. There's no need to avoid alcohol while taking rituximab. You're advised to stick within the guidelines of drinking no more than 14 units a week and that they should spread them out over the course of the week. In some cases, your doctor may advise lower limits.
Will I lose my hair with rituximab?
You could lose all your hair. This includes your eyelashes, eyebrows, underarm, leg and sometimes pubic hair. Your hair will usually grow back once treatment has finished but it is likely to be softer. It may grow back a different colour or be curlier than before.
What is the success rate of rituximab?
Rituximab with bendamustine (Treanda, Cephalon) was studied in a phase 2 trial in patients with relapsed disease. This combination was found to be very effective, with an ORR of 92%.
What is AbbVie Assistance Program?
myAbbVie Assist provides free medicine to qualifying patients. If you are uninsured or have limited insurance coverage, you may be eligible to receive prescribed AbbVie medication at no cost from our Program.
How do you qualify for free eliquis?
You may be eligible for the Free 30-Day Trial Offer for ELIQUIS® (apixaban) if:You have not previously filled a prescription for ELIQUIS;You have a valid 30-day prescription for ELIQUIS;You are being treated with ELIQUIS for an FDA-approved indication that an HCP has planned for more than 35 days of treatment;More items...
How do I contact AbbVie?
If you have questions, call us at 1-800-222-6885.
Why am I so tired after Rituxan?
Serious side effects that can occur with Rituxan include: tumor lysis syndrome (nausea, vomiting, diarrhea, and tiredness that happen due to tumor cells breaking down and releasing their contents into your blood)
Can rituximab cause weight gain?
In one study, people with low-grade, B-cell NHL had chemotherapy with the drugs cyclophosphamide, vincristine, and prednisone. Some people took Rituxan afterward and some people didn't take any medication. Of the people who took Rituxan after chemotherapy, 11% gained weight.
Can you drive after Rituxan infusion?
Talk to your doctor if you have any questions about your treatment with RITUXAN. The medicines that are given to help reduce severe infusion-related reactions may make you drowsy or dizzy, so it is a good idea to have someone else drive you home after treatments.
How long does it take to recover from rituximab?
Immune reconstitution starts usually after six months with recovery to normal between nine to twelve months. Extended rituximab treatment results in a prolonged recovery of B-cells without an increase of clinically relevant infections.
What is the most common side effect of Rituxan?
The most common side effects during treatment with Rituxan are: infusion-related reactions. infections (may include fever, chills) body aches.
What does rituximab do to your body?
Rituximab is used to treat certain types of cancer (such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia). It works by slowing or stopping the growth of cancer cells. Some brands of rituximab are also used to treat rheumatoid arthritis and can decrease joint pain and swelling.
How do you feel after an infusion?
The signs of infusion reaction typically include:cough.facial flushing.fever, chills.headache.itching.muscle or joint pain and stiffness.nausea.rash or hives.More items...•
How long after Rituxan infusion can you have a reaction?
Infusion-Related Reactions: Infusion-related reactions are very common side effects of Rituxan treatment. Serious infusion-related reactions can happen during your infusion or within 24 hours after your infusion of Rituxan. Your healthcare provider should give you medicines before your infusion of Rituxan to decrease your chance of having a severe infusion-related reaction.
How to report side effects of Genentech?
Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at (800) FDA‐1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835‐2555.
Can you test if you are pregnant before taking Rituxan?
Your healthcare provider should do a pregnancy test to see if you are pregnant before starting Rituxan.
Does Rituxan cause heart problems?
Heart Problems: Rituxan may cause chest pain, irregular heartbeats, and heart attack. Your healthcare provider may monitor your heart during and after treatment with Rituxan if you have symptoms of heart problems or have a history of heart problems. Tell your healthcare provider right away if you have chest pain or irregular heartbeats during treatment with Rituxan
How many patients tested positive for anti-rituximab?
A total of 273/2578 (11%) patients with RA tested positive for anti-rituximab antibodies at any time after receiving Rituxan. Anti-rituximab antibody positivity was not associated with increased infusion-related reactions or other adverse reactions. Upon further treatment, the proportions of patients with infusion-related reactions were similar between anti-rituximab antibody positive and negative patients, and most reactions were mild to moderate. Four anti-rituximab antibody positive patients had serious infusion-related reactions, and the temporal relationship between anti-rituximab antibody positivity and infusion-related reaction was variable. The clinical relevance of anti-rituximab antibody formation in Rituxan-treated patients is unclear.
How long before a course of Rituxan can you administer non live shots?
For patients treated with Rituxan, physicians should review the patient’s vaccination status and patients should, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating Rituxan and administer non-live vaccines at least 4 weeks prior to a course of Rituxan.
How long after Rituxan infusion do you have an adverse reaction?
Infusion-Related Reactions: In the Rituxan RA pooled, placebo-controlled studies, incidence of any adverse event within 24 hours of an infusion was 32% vs 23% after the first infusion, and 11% vs 13% after the second infusion in the Rituxan-treated patients and placebo group, respectively. Incidence of acute infusion-related reactions was 27% vs 19% after the first infusion, 9% vs 11% after the second infusion in the Rituxan-treated patients and placebo group, respectively. Serious acute infusion-related reactions were experienced by <1% of patients in either treatment group. Acute infusion-related reactions required dose modification (stopping, slowing, or interruption of the infusion) in 10% and 2% of patients receiving Rituxan or placebo, respectively, after the first course.
What is the most common infection with Rituxan?
The most common serious infection was pneumonia. Hypogammaglobulinemia: Hypogammaglobulinemia (IgA, IgG, or IgM below the lower limit of normal) has been observed in patients with GPA and MPA treated with Rituxan in GPA/MPA Study 1.
How long does it take for a patient to reactivate HBV?
HBV reactivation has been reported up to 24 months following completion of Rituxan therapy.
What is the rate of serious infections with Rituxan?
In the experience with Rituxan in 2578 RA patients, the rate of serious infection was 4.31 per 100 patient-years. The most common serious infections (≥0.5%) were pneumonia or lower respiratory tract infections, cellulitis, and urinary tract infections. Fatal serious infections included pneumonia, sepsis, and colitis. Rates of serious infection remain stable in patients receiving subsequent courses.
How long does it take for a PV to test positive for Rituximab?
Using a new ELISA assay, a total of 19/34 (56%) patients with PV treated with the Ritux 3 regimen tested positive for anti-rituximab antibodies by 18 months. The clinical relevance of anti-rituximab antibody formation in Rituxan treated PV patients is unclear.
What is rituximab used for?
Rituximab is a type of medication called a monoclonal antibody. It is used to treat certain types of cancer (e.g., non- Hodgkin's lymphoma).
Can rituximab cause heart problems?
WARNING: Rarely, serious (even fatal) side effects have occurred with rituximab use. Side effects such as breathing trouble, chest pain, irregular heartbeats, or a large change in amount of urine must be reported to your doctor immediately. Your doctor may stop rituximab or use additional treatment. Laboratory tests (e.g., electrolytes, kidney function) may be performed to monitor your progress. If you have heart or lung problems, a large number of cancer cells (above 25,000/mm3) in the blood, or certain cancers (CLL or lymphoma), you should be closely monitored.
How many patients tested positive for anti-rituximab?
A total of 273/2578 (11%) patients with RA tested positive for anti-rituximab antibodies at any time after receiving Rituxan. Anti-rituximab antibody positivity was not associated with increased infusion-related reactions or other adverse reactions. Upon further treatment, the proportions of patients with infusion-related reactions were similar between anti-rituximab antibody positive and negative patients, and most reactions were mild to moderate. Four anti-rituximab antibody positive patients had serious infusion-related reactions, and the temporal relationship between anti-rituximab antibody positivity and infusion-related reaction was variable. The clinical relevance of anti-rituximab antibody formation in Rituxan-treated patients is unclear.
How long before a course of Rituxan can you administer non live shots?
For patients treated with Rituxan, physicians should review the patient’s vaccination status and patients should, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating Rituxan and administer non-live vaccines at least 4 weeks prior to a course of Rituxan.
How long after Rituxan infusion do you have an adverse reaction?
Infusion-Related Reactions: In the Rituxan RA pooled, placebo-controlled studies, incidence of any adverse event within 24 hours of an infusion was 32% vs 23% after the first infusion, and 11% vs 13% after the second infusion in the Rituxan-treated patients and placebo group, respectively. Incidence of acute infusion-related reactions was 27% vs 19% after the first infusion, 9% vs 11% after the second infusion in the Rituxan-treated patients and placebo group, respectively. Serious acute infusion-related reactions were experienced by <1% of patients in either treatment group. Acute infusion-related reactions required dose modification (stopping, slowing, or interruption of the infusion) in 10% and 2% of patients receiving Rituxan or placebo, respectively, after the first course.
How long does it take for a patient to reactivate HBV?
HBV reactivation has been reported up to 24 months following completion of Rituxan therapy.
What is the rate of serious infections with Rituxan?
In the experience with Rituxan in 2578 RA patients, the rate of serious infection was 4.31 per 100 patient-years. The most common serious infections (≥0.5%) were pneumonia or lower respiratory tract infections, cellulitis, and urinary tract infections. Fatal serious infections included pneumonia, sepsis, and colitis. Rates of serious infection remain stable in patients receiving subsequent courses.
How long does it take for a PV to test positive for Rituximab?
Using a new ELISA assay, a total of 19/34 (56%) patients with PV treated with the Ritux 3 regimen tested positive for anti-rituximab antibodies by 18 months. The clinical relevance of anti-rituximab antibody formation in Rituxan treated PV patients is unclear.
What is the most common infection in Rituxan?
The incidence of serious infections was 11% vs 10% (Rituxan-treated vs cyclophosphamide, respectively), with rates of approximately 25 and 28 per 100 patient-years, respectively. The most common serious infection was pneumonia.
How many patients tested positive for anti-rituximab?
A total of 273/2578 (11%) patients with RA tested positive for anti-rituximab antibodies at any time after receiving Rituxan. Anti-rituximab antibody positivity was not associated with increased infusion-related reactions or other adverse reactions. Upon further treatment, the proportions of patients with infusion-related reactions were similar between anti-rituximab antibody positive and negative patients, and most reactions were mild to moderate. Four anti-rituximab antibody positive patients had serious infusion-related reactions, and the temporal relationship between anti-rituximab antibody positivity and infusion-related reaction was variable. The clinical relevance of anti-rituximab antibody formation in Rituxan-treated patients is unclear.
How long before a course of Rituxan can you administer non live shots?
For patients treated with Rituxan, physicians should review the patient’s vaccination status and patients should, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating Rituxan and administer non-live vaccines at least 4 weeks prior to a course of Rituxan.
How long after Rituxan infusion do you have an adverse reaction?
Infusion-Related Reactions: In the Rituxan RA pooled, placebo-controlled studies, incidence of any adverse event within 24 hours of an infusion was 32% vs 23% after the first infusion, and 11% vs 13% after the second infusion in the Rituxan-treated patients and placebo group, respectively. Incidence of acute infusion-related reactions was 27% vs 19% after the first infusion, 9% vs 11% after the second infusion in the Rituxan-treated patients and placebo group, respectively. Serious acute infusion-related reactions were experienced by <1% of patients in either treatment group. Acute infusion-related reactions required dose modification (stopping, slowing, or interruption of the infusion) in 10% and 2% of patients receiving Rituxan or placebo, respectively, after the first course.
What is the most common infection with Rituxan?
The most common serious infection was pneumonia. Hypogammaglobulinemia: Hypogammaglobulinemia (IgA, IgG, or IgM below the lower limit of normal) has been observed in patients with GPA and MPA treated with Rituxan in GPA/MPA Study 1.
How long does it take for a patient to reactivate HBV?
HBV reactivation has been reported up to 24 months following completion of Rituxan therapy.
What is the rate of serious infections with Rituxan?
In the experience with Rituxan in 2578 RA patients, the rate of serious infection was 4.31 per 100 patient-years. The most common serious infections (≥0.5%) were pneumonia or lower respiratory tract infections, cellulitis, and urinary tract infections. Fatal serious infections included pneumonia, sepsis, and colitis. Rates of serious infection remain stable in patients receiving subsequent courses.
How long does it take for a PV to test positive for Rituximab?
Using a new ELISA assay, a total of 19/34 (56%) patients with PV treated with the Ritux 3 regimen tested positive for anti-rituximab antibodies by 18 months. The clinical relevance of anti-rituximab antibody formation in Rituxan treated PV patients is unclear.
Can you breastfeed after rituximab?
There are no data on the presence of rituximab in human milk, the effect on the breastfed child, or the effect on milk production. Since many drugs including antibodies are present in human milk, advise a lactating woman not to breastfeed during treatment and for at least 6 months after the last dose of TRUXIMA due to the potential for serious adverse reactions in breastfed infants
Can rituximab cause fatal reactions?
Infusion-Related Reactions: Administration of rituximab products, including TRUXIMA, can result in serious, including fatal, infusion-related reactions. Deaths within 24 hours of rituximab infusion have occurred. Approximately 80% of fatal infusion-related reactions occurred in association with the first infusion. Monitor patients closely. Discontinue TRUXIMA infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion-related reactions
Can rituximab cause cardiac shock?
Cardiac adverse reactions, including ventricular fibrillation, myocardial infarction, and cardiogenic shock may occur in patients receiving rituximab products. Discontinue infusions for serious or life-threatening cardiac arrhythmias. Perform cardiac monitoring during and after all infusions of TRUXIMA for patients who develop clinically significant arrhythmias, or who have a history of arrhythmia or angina
Can rituximab cause lichenoid dermatitis?
Muco cutaneous reactions, some with fatal outcome, can occur in patients treated with rituximab products. These reactions include paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis. The onset of these reactions has been variable and includes reports with onset on the first day of rituximab exposure. Discontinue TRUXIMA in patients who experience a severe mucocutaneous reaction. The safety of re-administration of rituximab products to patients with severe mucocutaneous reactions has not been determined
Can rituximab cause renal failure?
Severe, including fatal, renal toxicity can occur after rituximab product administration in patients with NHL. Renal toxicity has occurred in patients who experience tumor lysis syndrome and in patients with NHL administered concomitant cisplatin therapy during clinical trials. The combination of cisplatin and TRUXIMA is not an approved treatment regimen. Monitor closely for signs of renal failure and discontinue TRUXIMA in patients with a rising serum creatinine or oliguria
